Table 6 Analysis of clinical and laboratorial parameters according to improvement (group 1A) or not (group 1B) of the EQ-5D utility index after vitamin D supplementation

BMI (kg/m²)

24 ± 4

24 ± 4

22 ± 3

22 ± 2

NS

Peripheral neuropathy yes/no (%)

(13/54)

25%

(8/54)

16%

(1/10)

10%

(1/10)

10%

NS

Basal insulin dose (IU)

36 ± 18

37 ± 19

33 ± 18

30 ± 14

NS

Prandial insulin dose (IU)

23 ± 11

24 ± 11

20 ± 13

21 ± 12

NS

25(OH)VD (ng/mL)

27 ± 9

57 ± 25

26 ± 8

52 ± 23

 < 0.001^a,b

HbA1c (%)

9.5 ± 2.4

9.6 ± 2.5

10.1 ± 2.4

10.6 ± 3.6

NS

HDL cholesterol (mg/dL)

47 ± 12

45 ± 10

50 ± 11

49 ± 13

NS

LDL cholesterol (mg/dL)

105 ± 33

105 ± 51

97 ± 19

122 ± 35

 < 0.005^b,*

Non-HDL cholesterol (mg/dL)

123 ± 41

122 ± 52

117 ± 23

147 ± 45

0.01^b

Triglycerides (mg/ dL)

97 ± 53

108 ± 75

101 ± 43

111 ± 53

NS

Albuminuria (mg/24 h – Log10)

1.25 ± 0.75

1.2 ± 0.75

1.27 ± 0.68

1.24 ± 0.4

 < 0.05^a